[Hepatic tolerance of aceclofenac]

Area of Science:

• Pharmacology
• Hepatology
• Rheumatology

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed for rheumatological conditions.
• Hepatotoxicity is a known, albeit rare, side effect associated with NSAID use.
• Aceclofenac (AC) is a commonly used NSAID for managing pain and inflammation in rheumatic diseases.

Purpose of the Study:

• To evaluate the potential hepatotoxic effects of aceclofenac (AC) in patients with various rheumatological pathologies.
• To assess changes in liver function, specifically transaminase levels (GOT and GPT), during AC treatment.

Main Methods:

• A cohort of 73 patients with diverse rheumatological conditions received aceclofenac (AC) 100 mg every 12 hours.
• Serum levels of aspartate aminotransferase (GOT) and alanine aminotransferase (GPT) were measured before and after the treatment period.
• Patient demographics, diagnoses, and treatment durations were recorded.

Main Results:

• The mean GOT levels remained stable, increasing from 16.6 U to 17.01 U, and mean GPT levels increased from 15.84 U to 16.53 U.
• Only one patient experienced a transient increase in GOT (20 U to 50 U) and one patient in GPT (32 U to 47 U), without clinical significance.
• No significant adverse liver events were reported across the study population.

Conclusions:

• Aceclofenac (AC) administration at standard therapeutic doses did not result in significant liver damage in patients with rheumatological diseases.
• The study supports the safety profile of aceclofenac concerning hepatotoxicity in this patient cohort.
• Routine monitoring of liver function may not be necessary for all patients on short-term aceclofenac therapy.